HAEM4:Hairy Cell Leukemia: Difference between revisions
Bailey.Glen (talk | contribs) Created page with "==Primary Author(s)*== *Snehal Patel, MD, PhD __TOC__ ==Cancer Category/Type== *Mature B-Cell Neoplasm ==Cancer Sub-Classification / Subtype==..." |
Bailey.Glen (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Hairy Cell Leukemia}} | |||
<blockquote class='blockedit'>{{Box-round|title=PREVIOUS EDITION|This page from the 4th edition of Haematolymphoid Tumours is being updated. See 5th edition [[HAEM5:Table_of_Contents|Table of Contents]]. | |||
}}</blockquote> | |||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 6: | Line 11: | ||
==Cancer Category/Type== | ==Cancer Category/Type== | ||
*[[Mature B-Cell Neoplasms|Mature B-Cell Neoplasm]] | *[[HAEM4:Mature B-Cell Neoplasms|Mature B-Cell Neoplasm]] | ||
==Cancer Sub-Classification / Subtype== | ==Cancer Sub-Classification / Subtype== | ||
| Line 169: | Line 174: | ||
<sup>‡</sup>Specific mutations in these genes can be found in [https://www.cbioportal.org/ cBioPortal] and [https://cancer.sanger.ac.uk/cosmic COSMIC]. | <sup>‡</sup>Specific mutations in these genes can be found in [https://www.cbioportal.org/ cBioPortal] and [https://cancer.sanger.ac.uk/cosmic COSMIC]. | ||
'''*'''The WHO states that BRAF p.Val600Glu is detected in virtually all cases and notes that the classification of B-cell leukemias that are immunophenotypically and morphologically classified as HCL but lack BRAF activating mutations (but instead have MAP2K1 activating mutations and use the IGHV4-34 gene segment) is uncertain. These seem to be more similar molecularly and clinically to [[ | '''*'''The WHO states that BRAF p.Val600Glu is detected in virtually all cases and notes that the classification of B-cell leukemias that are immunophenotypically and morphologically classified as HCL but lack BRAF activating mutations (but instead have MAP2K1 activating mutations and use the IGHV4-34 gene segment) is uncertain. These seem to be more similar molecularly and clinically to [[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|HCLv]]. | ||
*BRAF and MAP2K1 activating mutations are mutually exclusive | *BRAF and MAP2K1 activating mutations are mutually exclusive | ||
| Line 224: | Line 229: | ||
|BRAF p.Val600Glu | |BRAF p.Val600Glu | ||
|Diagnostic | |Diagnostic | ||
|May be useful when immunophenotype is equivocal; Excludes [[ | |May be useful when immunophenotype is equivocal; Excludes [[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|HCLv]] | ||
|- | |- | ||
|MAP2K1 | |MAP2K1 | ||
| Line 252: | Line 257: | ||
==Links== | ==Links== | ||
*[[ | *[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
*[[Splenic | *[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma]] | ||
==References== | ==References== | ||
| Line 264: | Line 269: | ||
==Notes== | ==Notes== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | ||
[[Category:HAEM4]] [[Category:DISEASE]] | |||